Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Drops By 21.2%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 13,400 shares, a decrease of 21.2% from the October 15th total of 17,000 shares. Based on an average trading volume of 43,500 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A number of hedge funds have recently added to or reduced their stakes in the stock. Atria Investments Inc purchased a new stake in Global X Genomics & Biotechnology ETF during the third quarter valued at $122,000. Centaurus Financial Inc. purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the 2nd quarter valued at about $146,000. James J. Burns & Company LLC bought a new position in shares of Global X Genomics & Biotechnology ETF in the 2nd quarter worth approximately $181,000. Rockefeller Capital Management L.P. purchased a new position in shares of Global X Genomics & Biotechnology ETF in the third quarter worth approximately $205,000. Finally, Insight Advisors LLC PA grew its position in Global X Genomics & Biotechnology ETF by 59.0% during the second quarter. Insight Advisors LLC PA now owns 21,177 shares of the company’s stock valued at $221,000 after buying an additional 7,861 shares during the period. 56.95% of the stock is currently owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of GNOM traded down $0.55 during mid-day trading on Friday, hitting $9.65. 81,908 shares of the company traded hands, compared to its average volume of 57,130. The stock has a market cap of $70.54 million, a price-to-earnings ratio of -4.12 and a beta of 1.03. The stock has a 50-day moving average price of $10.87 and a two-hundred day moving average price of $10.87. Global X Genomics & Biotechnology ETF has a 1 year low of $9.57 and a 1 year high of $12.53.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.